News

Glaukos noted under the updated labeling, physicians may now re-administer iDose TR more than once in patients who maintain a healthy cornea, as defined by corneal endothelial cell density parameters.

Two recent journal articles underscore the organ’s importance in identifying systemic disease processes.

The study looked at 128 eyes in 64 patients before and after they had received the vaccine.

FDA authorizes compassionate use of urcosimod for neuropathic corneal pain, a condition that causes severe pain and sensitivity of the eyes, face, or head.

Bisant A. Labib, OD, FAAO, DipAAO, gives her insights on the causes and management of anterior uveitis during Island Eyes 2026.

The Bimatoprost Drug Pad-IOL System is intended for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Lens thickness and ciliary muscle are not affected by low-dose pilocarpine.

Benjamin P. Casella, OD, FAAO, shares perspectives on the most impactful glaucoma developments from the past year and the future role of interventional and personalized care.

Data estimates the prevalence of glaucoma currently is almost 50% higher than previously estimated and over 1.6 million individuals in the UK are estimated to have glaucoma by 2060.

The investigational new drug (IND) application from Complement Therapeutics for CTx001 was previously approved by the FDA in October 2025.

ODs are gearing up for anticipated advancements in specialty lens and lenses for myopia management and patients with astigmatism.

Understanding AMD pathophysiology through nutrition has helped shape the disease’s detection and management.

Kuzniar's OGSLS 2026 poster presentation provides a follow-up to previous fitting findings for the Zenlens Chroma HOA lens.

Key clinical trial data and PDUFA dates in early 2026 focus on treatments for dry eye, age-related macular degeneration, and rare eye diseases.

A total of 38 patients were included in the study. All underwent implantation of the PRIMAretinal prosthetic chip with the goal of restoring vision.

The state of the eye’s surface is just as important a factor as accurate measurements when determining the correct IOL.

Jason Jedlicka, OD, FAAO, talks through a presentation he gave during last week's conference.

Previously, the EDOF technology was specifically limited to intraocular lenses.

Employers are obliged to provide employees with appropriate safety eyewear and face protection that conforms to the industry standard.

Chronic ocular diseases and ocular surface diseases alike now have new treatment options.

“Remarkable” results were reportedly obtained with hypotony with hydroxypropyl methylcellulose.

Susan Gromacki, OD, MS, FAAO, FSLS, details her presentation given at this year's conference.

Jamie Kuzniar, OD, FAAO, FSLS, details a poster presentation that served as a follow-up to results of previous fittings of Zenlens Chroma HOA (Bausch + Lomb).

Jason Jedlicka, OD, overviews his poster, “A Custom Wavefront-Guided Scleral Lens System For Higher Order Aberrations: Real-World Early Experience From a Retrospective Multicenter Case Review.”

New clinical data and trial updates closed out 2025.

A unique case study of HZO featuring Steve Silberberg, OD, DipABO, as the patient.

The lens was developed in collaboration with Brien Holden Vision Institute (BHVI).

Kramer, OD, FAAO, FSLS, presented alongside Kelsea Skidmore, OD, MS; Vivien Tse, OD; and Elaine Chen, OD, at this year's conference.